CHANGES IN THE COMPOSITION OF BIOLOGICAL FLUIDS IN ONCOLOGICAL DISEASES

Authors

  • E'zoza Toxirova a student of the 2nd Faculty of General Medicine, Foreign Students' Group, Tashkent State Medical University
  • Tursunoy Ergashboy qizi Khomidova Scientific supervisor: PhD Lecturer, Department of Normal and Pathological Physiology

Keywords:

oncological diseases, cancer, biological fluids, biomarkers, blood, urine, saliva, circulating tumor DNA, liquid biopsy, metabolites.

Abstract

 Oncological diseases are associated with complex molecular, metabolic, biochemical, and immunological alterations that may be reflected in the composition of biological fluids. Blood, urine, saliva, and cerebrospinal fluid contain numerous molecules capable of reflecting pathological processes associated with tumor development and progression. These include circulating tumor DNA, cell-free DNA, circulating tumor cells, proteins, cytokines, metabolites, microRNAs, and extracellular vesicles. The analysis of such components has become an important area of modern oncology because biological fluids can be collected with considerably less invasiveness than tissue biopsies. The present article reviews the principal changes occurring in biological fluids during malignant diseases and discusses their potential diagnostic and monitoring significance. Particular attention is given to biochemical changes in blood, molecular and metabolic alterations in urine, and the emerging role of salivary biomarkers. The integration of conventional biochemical parameters with molecular biomarkers may contribute to the development of more informative and minimally invasive approaches to cancer assessment. [1–5]

References

Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 2022;12(1):31–46.

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249.

Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics. 2019;20:71–88.

Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. 2017;17:223–238.

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nature Reviews Clinical Oncology. 2021;18:297–312.

Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 2014;6(224):224ra24.

Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nature Reviews Cancer. 2011;11:426–437.

McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Current Opinion in Clinical Nutrition and Metabolic Care. 2009;12(3):223–226.

Scott HR, McMillan DC, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. British Journal of Cancer. 2002;87:264–267.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.

Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metabolism. 2016;23(1):27–47.

Jobard E, Trédan O, Postoly D, et al. A systematic review of urinary biomarkers for cancer detection. Clinical Proteomics. 2017;14:21.

Dijkstra S, Birker IL, Smit FP, et al. Urinary biomarkers for cancer diagnosis and surveillance: current evidence and future perspectives. International Journal of Cancer. 2023.

Dinges SS, Hohm A, Vandergrift LA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations. Nature Reviews Urology. 2019;16(6):339–362.

Serkies K, et al. Urine biomarkers in cancer detection: a systematic review of preanalytical parameters and applied methods. International Journal of Cancer. 2023.

Pan W, et al. Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions. International Journal of Surgery. 2026.

Zhang L, Xiao H, Wong DT. Salivary biomarkers for clinical applications. Molecular Diagnosis & Therapy. 2009;13:245–259.

Zhang CZ, Cheng XQ, Li JY, et al. Saliva in the diagnosis of diseases. International Journal of Oral Science. 2016;8:133–137.

Vats R, Yadav P, Bano A, et al. Salivary biomarkers in non-invasive oral cancer diagnostics: a comprehensive review. Journal of Applied Oral Science. 2024;32:e20240151.

Li Y, et al. Salivary biomarkers for cancer diagnosis: a meta-analysis. Clinical Oral Investigations. 2020.

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). Journal of Extracellular Vesicles. 2018;7(1):1535750.

Downloads

Published

2026-09-22